BORTEZOMIB ACCORD, BORTEZOMIB INTAS (Accord Healthcare Pty Ltd)

BORTEZOMIB ACCORD, BORTEZOMIB INTAS (powder for injection), in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.

BORTEZOMIB ACCORD, BORTEZOMIB INTAS, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.

BORTEZOMIB ACCORD, BORTEZOMIB INTAS is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

BORTEZOMIB ACCORD, BORTEZOMIB INTAS in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.